0Q1G Stock Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Eli Lilly and Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$540.00 |
| 52 Week High | US$540.00 |
| 52 Week Low | US$540.00 |
| Beta | 0.32 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 3,461.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0Q1G | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | -2.0% | -0.01% |
| 1Y | n/a | -4.9% | 0.8% |
Return vs Industry: Insufficient data to determine how 0Q1G performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 0Q1G performed against the UK Market.
Price Volatility
| 0Q1G volatility | |
|---|---|
| 0Q1G Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 8.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0Q1G has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0Q1G's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1876 | 43,000 | Dave Ricks | https://www.lilly.com |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
Eli Lilly and Company Fundamentals Summary
| 0Q1G fundamental statistics | |
|---|---|
| Market cap | CHF610.39b |
| Earnings (TTM) | CHF4.62b |
| Revenue (TTM) | CHF30.07b |
132.2x
P/E Ratio20.3x
P/S RatioIs 0Q1G overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0Q1G income statement (TTM) | |
|---|---|
| Revenue | US$34.12b |
| Cost of Revenue | US$7.08b |
| Gross Profit | US$27.04b |
| Other Expenses | US$21.80b |
| Earnings | US$5.24b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 5.82 |
| Gross Margin | 79.25% |
| Net Profit Margin | 15.36% |
| Debt/Equity Ratio | 233.4% |
How did 0Q1G perform over the long term?
See historical performance and comparison